Serina Therapeutics, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $130,000 | $56,000 | $3.2M | $34,000 | $144,000 |
| Cost of revenue | — | — | $40,000 | $13,000 | $19,000 |
| Gross profit | — | — | $102,000 | $21,000 | $125,000 |
| Research and development | $13.2M | $7.5M | $2.4M | $1.0M | $1.5M |
| Operating expenses | $24.2M | $17.1M | $6.3M | $7.0M | $8.2M |
| Operating income | -$24.0M | -$17.0M | -$3.1M | -$7.0M | -$7.9M |
| Interest expense | $213,000 | $526,000 | $4.9M | $3.3M | $1.1M |
| Pretax income | -$19.2M | -$11.2M | $5.3M | $10.5M | $8.7M |
| Income tax expense | $18,000 | $0 | $0 | — | — |
| Net income | -$19.2M | -$11.1M | $5.3M | -$10.5M | -$8.7M |
| Balance Sheet | |||||
| Cash and equivalents | $3.1M | $3.7M | $7.6M | $645,000 | $584,000 |
| Current assets | $6.1M | $5.7M | $7.6M | $2.5M | $2.2M |
| Total assets | $7.0M | $6.7M | $9.0M | $3.2M | $3.2M |
| Current liabilities | $3.6M | $2.4M | $1.4M | $10.1M | $9.0M |
| Total liabilities | $7.0M | $6.2M | $4.9M | $20.6M | $15.0M |
| Total debt | — | — | — | $21.4M | $14.7M |
| Stockholders' equity | -$37,000 | $641,000 | -$32.3M | -$17.2M | -$11.8M |
| Cash Flow Statement | |||||
| Cash from operations | -$18.0M | -$17.1M | -$2.5M | -$5.9M | -$7.9M |
| Depreciation and amortization | $100,000 | $100,000 | $90,000 | — | — |
| Stock-based compensation | $3.8M | $2.6M | $25,000 | $760,000 | $999,000 |
| Capital expenditure | $59,000 | $22,000 | $504,000 | — | — |
| Free cash flow | -$18.0M | -$17.2M | -$3.0M | — | — |
| Impairments | $0 | $0 | $0 | — | — |
Shares outstanding 15.0M · Free float 28.9%
Annual filing data through FY ended December 31, 2025; float as of July 15, 2026.